Form Health review

Form Health publishes a $299-per-month self-pay option for people whose insurance does not cover the program. According to its official program and FAQ pages, this fee includes appointments with a Form clinician and Registered Dietitian, unlimited care-team messaging, and access to the Form platform. Laboratory work and prescription medication are not included. The fee is therefore a recurring clinical-program charge, not an all-inclusive GLP-1 price. Form also accepts many private insurance plans and Medicare. Under that model, eligible clinical visits, laboratory tests, and medications are billed through insurance, while the patient remains responsible for applicable copays, deductibles, coinsurance, and noncovered services. Form does not publish a single insured monthly price because patient responsibility depends on the exact health and pharmacy benefits. Medication cost also varies by the product prescribed, pharmacy, formulary status, and prior-authorization outcome. Form says its team reviews coverage and submits prior authorizations, but approval is ultimately controlled by the insurer. Before paying, request separate estimates for program care, laboratory work, and the likely prescription rather than comparing the $299 fee directly with competitors that bundle medication into one cash price.

Form Health states that it prescribes only FDA-approved medications when clinically appropriate and does not prescribe compounded weight-loss drugs. Its current medication page names Wegovy, containing semaglutide; Zepbound, containing tirzepatide; Foundayo, containing orforglipron; Saxenda, containing liraglutide; and Contrave, containing bupropion and naltrexone. Wegovy and Saxenda are GLP-1 receptor agonists, Zepbound targets GLP-1 and GIP receptors, and the FDA approved Foundayo as an oral GLP-1 medication in April 2026. Contrave is not a GLP-1 drug. FDA records support the weight-management approvals for Wegovy, Zepbound, and Foundayo. Form also says clinicians may prescribe FDA-approved medications whose labeled indications are diabetes, migraines, or other conditions. Its examples include Ozempic, Rybelsus, metformin, bupropion, naltrexone, topiramate, and zonisamide. That distinction matters: an FDA-approved product can still be prescribed off-label for weight management. Medication is not guaranteed by enrollment. A clinician reviews medical history, laboratory information, goals, contraindications, and insurance coverage before deciding whether a prescription is appropriate. Prescriptions are sent to the patient’s selected pharmacy rather than supplied as compounded medication through the membership.

Form Health operates as a longitudinal telehealth obesity clinic rather than a prescription-only service. It describes its care teams as being led by an American Board of Obesity Medicine-certified physician and supported by Advanced Practice Providers, Registered Dietitians, and specialized staff. Patients are assigned a Form clinician and dietitian, with monthly video appointments advertised for both roles. Between visits, members can message the care team through the Form app and use weight tracking, food-photo journaling, educational material, support groups, and monthly classes. Enrollment involves submitting insurance information and medical records, downloading the app, and scheduling initial visits with the clinician and dietitian. Form’s eligibility FAQ says applicants must be at least 18 and generally have a BMI of 30 or higher, or 27 or higher with a weight-related health risk. Applicants must also have an established primary-care clinician whom they visited within the previous 12 months. Form obtains medical records and says it coordinates care with that clinician because telehealth cannot replace every aspect of an in-person physical examination. Regular program participation is expected when medication is prescribed. Prospective patients should confirm who will conduct each appointment, whether the advertised monthly cadence applies to their plan, and how quickly messages are normally answered.

Begin by asking Form Health to verify that the program and assigned clinicians are in network for the exact insurance plan. Then confirm the information independently with the insurer, including telehealth benefits, nutrition visits, laboratory coverage, deductibles, and obesity-drug exclusions. A medical plan may cover Form’s appointments while the pharmacy plan excludes Wegovy, Zepbound, Foundayo, or another prescribed drug. Check the formulary and ask about prior-authorization, renewal, and step-therapy requirements. Self-pay patients should obtain written confirmation that the current $299 monthly fee includes clinician and Registered Dietitian visits, messaging, and platform access but excludes medication and laboratory charges. Ask which pharmacy will fill the prescription and verify that the product is an FDA-approved brand or generic medication rather than a compounded preparation. Form’s current policy says it does not prescribe compounded medication, and FDA materials confirm that compounded GLP-1 products are not FDA-approved. State access also deserves confirmation. Form’s support center says video care is available to people living in the United States, and its health-plan page describes a 50-state clinical network. Nevertheless, confirm availability for the patient’s physical location, insurance arrangement, and required clinician type. Finally, review cancellation terms and ask how prescriptions and records are transitioned when membership ends.

Form Health is a strong fit for adults seeking sustained obesity care rather than a fast GLP-1 prescription. Its combination of medical oversight, dietitian appointments, monthly follow-up, app messaging, and primary-care coordination may suit people who want more structure than prescription-focused telehealth services provide. It is particularly relevant for patients who prefer FDA-approved products and want to avoid compounded semaglutide or tirzepatide. Insurance may reduce clinical-service costs for some members, while the published $299 monthly self-pay option provides a clear fallback when program care is not covered. The main limitation is total-cost transparency. Self-pay medication and laboratory costs remain separate, and insured expenses depend on network status, deductibles, copays, pharmacy benefits, and prior authorization. Form is therefore less suitable for shoppers who require one predictable medication-inclusive cash price or direct medication shipment as part of membership. It also may not fit someone without a recent primary-care visit, someone unable to attend regular follow-up, or an applicant who does not meet the program’s clinical criteria. Services are limited to people living in the United States. Enrollment should never be interpreted as a guarantee of a GLP-1 prescription, pharmacy availability, or insurance approval.